tbuckley/cabot-search huggingface dataset:
Classification of Airflow Limitation Based on <i>z</i>-Score Underestimates Mortality in Patients with Chronic Obstructive Pulmonary Disease
Authors: Elena Tejero, Eva Prats, Raquel Casitas, Raúl Galera, Paloma Pardo, Adelaida Gavilán, Elisabet Martínez-Cerón, Carolina Cubillos-Zapata, Luis del Peso, Francisco García-Río
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Global Lung Function Initiative recommends reporting lung function measures as z-score, and a classification of airflow limitation (AL) based on this parameter has recently been proposed.To evaluate the prognostic capacity of the AL classifications based on z-score or percentage predicted of FEV1 in patients with chronic obstructive pulmonary disease (COPD).A cohort of 2,614 patients with COPD recruited outside the hospital setting was examined after a mean (± SD) of 57 ± 13 months of follow-up, totaling 10,322 person-years. All-cause mortality was analyzed, evaluating the predictive capacity of several AL staging systems.Based on Global Initiative for Chronic Obstructive Lung Disease guidelines, 461 patients (17.6%) had mild, 1,452 (55.5%) moderate, 590 (22.6%) severe, and 111 (4.2%) very severe AL. According to z-score classification, 66.3% of patients remained with the same severity, whereas 23.7% worsened and 10.0% improved. Unlike other staging systems, patients with severe AL according to z-score had higher mortality than those with very severe AL (increase of risk by 5.2 and 3.9 times compared with mild AL, respectively). The predictive capacity for 5-year survival was slightly higher for FEV1 expressed as percentage of predicted than as z-score (area under the curve: 0.714-0.760 vs. 0.649-0.708, respectively). A severity-dependent relationship between AL grades by z-score and mortality was only detected in patients younger than age 60 years.In patients with COPD, the AL classification based on z-score predicts worse mortality than those based on percentage of predicted. It is possible that the z-score underestimates AL severity in patients older than 60 years of age with severe functional impairment.
COLCHICINE INHIBITS PLATELET AGGREGATION IN VITRO BY INTERFERING WITH COFILIN AND LIM DOMAIN KINASE 1, THE MAIN KINASES INVOLVED IN CYTOSKELETON REARRANGEMENT
Authors: Giovanni Cimmino, Stefano Conte, Andrea Morello, Grazia Pellegrino, Alberto Morello, Saverio D'Elia, Gaetano Calì, Bruno Trimarco, Paolo Golino, Plinio Cirillo
Journal: Journal of the American College of Cardiology (2017)
A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data
Authors: I. Petrini, M. Lencioni, M. Ricasoli, M. Iannopollo, C. Orlandini, F. Oliveri, F. Filipponi, C. Bartolozzi, M. Del Tacca, S. Ricci
Journal: Journal of Clinical Oncology (2009)

4592 Background: S, an oral multi-kinase inhibitor that targets Raf-kinase and receptor tyrosine kinases, improved overall survival (OS) and time to progression (TTP) versus placebo in a randomized phase III study in HCC (SHARP study). The safety of S in association with infusional and bolus 5FU regimens was established in a previous PhI study, with no clinically relevant pharmacokinetic interaction between S and 5FU. The present trial was designed to evaluate the safety and efficacy of S with infusional 5FU in HCC pts. Methods: Patients with advanced HCC (not eligible to surgical or locoregional therapies), age≥18 years, Child-Pugh Class A or B, ECOG PS 0–1, without prior systemic treatment for HCC and adequate bone marrow, liver and renal function, were eligible for the study. The primary endpoint is the Disease Control Rate (DCR). Secondary endpoints included response rate, TTP, OS and safety. According to a two-step Simon's model 46 pts were to be accrued. Pts were treated with oral S 400 mg bid continuously and c.i. 5FU 200 mg/sqm/day day 1–14 every 3 weeks. Tumour response was assessed according to RECIST criteria every 9 weeks. Results: Between October 2006 and October 2008 38 pts were enrolled: M-F: 32–6, median age (range): 68(47–83) years, ECOG-PS 0–1: 28–10, Child-Pugh A-B: 35–3, extrahepatic spread: 14 pts, macroscopic vascular invasion: 6 pts. Grade 3/4 (%) toxicities (NCI CTC v 3.0 criteria) included diarrhoea 5/0, stomatitis 21/3, hand foot syndrome 21/0, skin rash 11/0, hypertension 11/0; hyperbilirubinemia 5/3, AST 11/0, ALT 8/0, cardiac toxicity (one cardiac failure, one atrial fibrillation) 5/0 and bleeding (melena) in 3/0. One partial response was observed. Stable disease was obtained in 45% of pts with a median duration of 9.6 months (range 5–18+). Median TTP was 7.6 months (CI 95%=5.3–9.9) and median OS 12.2 months (CI 95%=4.45–19.8). Conclusions: Preliminary results of this PhII study show encouraging disease control rate, TTP and OS in pts with advanced HCC. The S+5FU association is feasible, well tolerated and AEs were predictable and manageable. [Table: see text]
LONG-TERM PROGNOSTIC VALUE OF COMPUTED TOMOGRAPHY-DERIVED CORRECTED CONTRAST OPACIFICATION DECREASE IN PATIENTS WITH CORONARY STENOSIS
Authors: Dominik C. Benz, Fran Mikulicic, Christoph Gräni, Dominic Moret, Oliver Gaemperli, Ronny Buechel, Aju Paul Pazhenkottil, Philipp Kaufmann
Journal: Journal of the American College of Cardiology (2017)
Mystery of tumor specific immunity: LIGHT turns on silent tumor specific immunity
Authors: L. T. Cao
Journal: Journal of Clinical Oncology (2006)

20107 Background: More than 2000 tumor antigens have been identified so far. However, none of these tumor antigens are approved to be immunogenic. Genetic alteration which activates uncontrolled cell growth transforms normal cells to tumor cells. Tumor cells, therefore, do not carry any foreign antigens and thus tumor antigens are not immunogenic (unless in the presence of viral infection). The so-called tumor specific immunity is actually the host versus graft effect, not specific for tumors. Methods and Results: Using proper controlled tissue graft as control, our previous data indicated that the hosts could accept both the graft and the tumor. The immune system is silent to tumor antigens. By transfecting tumor cells with a modified LIGHT (Lymphotoxins, shows Inducible expression, and completes with herpes simplex virus Glycoprotein D for Herpes virus entry mediator, a receptor expressed by T lymphocytes) expressing vectors, Dr. Fu at the University of Chicago is able to eradicate tumors in his animal model. The expressed LIGHT on the tumor cell surface serves as tether for the naïve T cells and the stromal cells by binding to lymphotoxin-beta receptor on stromal cells and herpes virus entry mediator on T cells. The trio of tumor-LIGHT-stroma working like a foreign antigen attracts naïve T cells and increases the infiltration of naïve T cells within the tumors. The trio then co-activates naïve T cells to destroy tumors. The LIGHT mechanism may be similar to that in autoimmune phenomenon. Conclusion: Tumor specific immunity may be silent; however we can modify tumor antigens and activate silent immune system to destroy tumors. We currently have four immunotherapies against cancer. The LIGHT approach or in situ co-stimulation therapy, vaccine therapy, and ex vivo cell-transfer therapy are three active immunotherapies. The fourth one is a passive immunotherapy: the near-specific, personalized immunotherapy. No significant financial relationships to disclose.
FINAL 3-YEAR CLINICAL OUTCOMES OF PATIENTS TREATED WITH EVEROLIMUS-ELUTING BIORESORBABLE SCAFFOLDS VERSUS EVEROLIMUS-ELUTING METALLIC STENTS: A PROPENSITY SCORE COMPARISON OF PATIENTS ENROLLED IN THE EXTEND AND SPIRIT TRIALS
Authors: Jose de Ribamar Costa, Alexandre Abizaid, Antonio Bartorelli, Robert Whitbourn, Patrick Serruys
Journal: Journal of the American College of Cardiology (2017)
CORONARY MICROVASCULAR DYSFUNCTION AFFECTS THE MYOCARDIAL CONTRACTILE RESERVE IN WOMEN WITH ANGINA AND NO OBSTRUCTIVE CORONARY ARTERY DISEASE
Authors: Marie Mide Michelsen, Adam Pena, Naja Mygind, Ida Gustafsson, Nis Host, Jan Bech, Henrik Steen Hansen, Jens Kastrup, Peter Riis Hansen, Eva Prescott
Journal: Journal of the American College of Cardiology (2017)
ESTROGEN DEPRIVATION AGGRAVATES CARDIOMETABOLIC DYSFUNCTION AND INTRACELLULAR CALCIUM DYSHOMEOSTASIS IN OBESE-INSULIN RESISTANCE RATS
Authors: Siripong Palee, Wanitchaya Minta, Duangkamol Mantor, Wissuta Sutham, Wasana Pratchayasakul, Siriporn Chattipakorn, Nipon Chattipakorn
Journal: Journal of the American College of Cardiology (2017)
Phase I/II study of <sup>90</sup>Y-clivatuzumab tetraxetan (<sup>90</sup>Y-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results.
Authors: Allyson J. Ocean, Michael J. Guarino, Kenneth L. Pennington, Gregory M. Springett, Seza A Gulec, Tanios S. Bekaii-Saab, Alberto J. Montero, Edith P. Mitchell, John S. Kauh, Max W. Sung, David V. Gold, Heather Horne, William A. Wegener, David M. Goldenberg
Journal: Journal of Clinical Oncology (2012)

4043 Background: A Phase I/II trial evaluated single and repeated cycles of fractionated radioimmunotherapy (RAIT) with 90 Y-labeled humanized mAb ( 90 Y-hPAM4) plus Gem as first-line therapy in Stage 3-4 APC. Methods: Cycles of Gem once-weekly x 4 with 90 Y-hPAM4 on wks 2, 3 and 4 were repeated until progression, withdrawal or unacceptable toxicity. In Part I, 90 Y doses were escalated with Gem fixed at 200 mg/m 2 . In Part II, Gem was increased up to 1000 mg/m 2 , with 90 Y fixed at 12 mCi/m 2 for cycle 1 and lowered for retreatment. Results: Of 100 pts entered, 10 withdrew early, while 90 (73 stage IV) received 1-4 cycles. In Part I, 38 pts received 90 Y-hPAM4 weekly x 3 at 6.5, 9, 12, or 15 mCi/m 2 , with the same cycle repeated 1-3 times in 13 pts. By CT-RECIST criteria, 6 pts (16%) had PRs and 16 (42%) had stabilization as best response (58% disease control). After cycle 1, 52% (13/25) with PET-avid images had &gt;25% SUV reduction, and 33% (9/27) with elevated CA19-9 levels decreased by &gt;50%. The median OS was 7.7 mo., but 11.8 mo. for retreated pts [46% (6/13) survived ≥1 yr.], and with improved efficacy at higher 90 Y doses. NCI-CTCv3 Grade 3-4 platelets or ANC developed in 20/38 (53%) after cycle 1 (all reversible to Grade 1) and in all retreated pts (irreversible in 4/9 pts at 12 or 15 mCi/m 2 ). In Part II, 52 pts received increased Gem without evidence of improved efficacy, while 13 pts were retreated with more acceptable toxicity at lower 90 Y doses of 6.5 or 9 mCi/m 2 . Treatment was well tolerated with no infusion reactions. Infections requiring IV antibiotics occurred at a low rate and responded to appropriate coverage (bacteremia/sepsis, 7%; febrile neutropenia, 4%; ascending cholangitis, 3%; pneumonia, 2%; others 1%). One case of bleeding occurred, due to rectal tumor invasion. Anecdotal reports of good performance and decreased pain medication requirements require further validation. Conclusions: Fractionated RAIT with 90 Y-hPAM4 combined with low-dose 200 mg/m 2 GEM appears promising as a treatment regimen for APC. Hematologic toxicity was dose limiting. A 90 Y-hPAM4 dose of 12 mCi/m 2 for cycle 1 and 6.5 mCi/m 2 for cycle 2 have been selected as suitable for further clinical development in the first-line setting.
The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,
Authors: Christophe Desterke, Costanza Bogani, Lisa Pieri, Alessandro M. Vannucchi, Bernadette Guerton, Christophe Martinaud, Denis Clay, Jean-Jacques Lataillade, Hans Hasselbalch, Heinz Gisslinger, Sophie Amsellem, Jean-Loup Demory, Agnès Charpentier, Brigitte Dupriez, Claude Boucheix, Eric Rubinstein, Marie-Caroline Le Bousse-Kerdiles
Journal: Blood (2011)
Negative Psychosis Prevention Trials
Authors: Paolo Fusar-Poli
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
BASELINE ABSENCE OF ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY IS ASSOCIATED WITH INCREASED MORTALITY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Ajayram Ullal, Polydoros Kampaktsis, Rajesh Swaminathan, Shing-Chiu Wong, Robert Minutello, Dmitriy Feldman, Geoffrey Bergman, Luke Kim, Harsimran Singh, Peter Okin
Journal: Journal of the American College of Cardiology (2017)
The Combined Evaluation of Neutrophil, T-Lymphocyte and Monocyte Counts Provides New Prognostic Information in CLL Patients
Authors: Annalisa Chiarenza, Nunziatina Laura Parrinello, Anna Maria Triolo, Giuseppina Rizzo, Alessandra Romano, Cinzia Maugeri, Laura Anastasia Caruso, Giovanna Motta, Amalia Figuera, Angelo Curto Pelle, Valerio Leotta, Mary Ann Di Giorgio, Piera La Cava, Cesarina Giallongo, Daniele Tibullo, Francesco Di Raimondo
Journal: Blood (2016)
NOVEL NON-INVASIVE LEFT VENTRICULAR STIFFNESS INDEX IN PATIENTS WITH LOW-FLOW COMPARED TO NORMAL-FLOW SEVERE AORTIC STENOSIS WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION
Authors: Nicholas Ngiam, Benjamin Tan, Ching-Hui Sia, Hui-Wen Sim, Elaine Boey, William K.F. Kong, Tiong Cheng Yeo, Kian Keong Poh
Journal: Journal of the American College of Cardiology (2017)
Apoptosis Induction in Cutaneous T-Cell Lymphoma Cells after Treatment with Lenalidomide
Authors: Vassiliki Bakou, Evangelia Papadavid, Aris Spathis, Frieda Kontsioti, Sotiris Papageorgiou, Efthimia Bazani, Diamantina Vasilatou, Konstantinos Gkontopoulos, Georgia Stavroulaki, Irene Glezou, Petros Karakitsos, Dimitrios Rigopoulos, George Dimitriadis, Vassiliki Pappa
Journal: Blood (2016)
Influence of the dramatic fall of hormone replacement therapy (HRT) prescription on postmenopausal breast cancer incidence: The Austrian data
Authors: G. Pfeiler, C. Glatz, R. Königsberg, C. Vutuc, E. Kubista, C. Singer
Journal: Journal of Clinical Oncology (2009)

1529 Background: The Women's Health Initiative trial showed a significant increase in breast cancer risk among women using HRT. This publication led to a dramatic fall in HRT prescription worldwide. Several studies argued that the ensuing decline in breast cancer incidence among postmenopausal women was due to the reduced HRT prescriptions. We have investigated whether the strong decline in HRT prescription in Austrian women from 2002 onward was associated with a decrease in postmenopausal breast cancer incidence in Austria. Methods: Breast cancer incidence data were obtained from the National Austrian Cancer Registry. HRT prescription data were calculated using Pharmaceutical Benefits Scheme data. Hormone receptor expression data were taken from the pathology report of all patients with breast cancer, who were operated on at the Division of Special Gynecology, as well as the Department of Surgery, Medical University of Vienna (MUW), from 1998 to 2000, and 2005 to 2007, respectively. Chi-Square test was used to identify significant differences. Results: HRT prescription slightly increased from 1998 to 2000, but dramatically decreased by 70% after 2003, reaching a significantly lower level. When comparing breast cancer incidence data from 1999 and 2004, a nonsignificant trend toward a decreased incidence in 50- to 54-year-old women could be observed. Comparing predicted breast cancer incidence for 2004 with the actual incidence for 2004 in this group, a significant decrease could be demonstrated. Ten percent to 12% of all new breast cancers in Austria are treated at the MUW every year. Regarding histopathologic breast cancer parameters of patients treated at the MUW from 1998 to 2000 and 2005 to 2007, respectively, a nonsignificant decline of hormone receptor positive tumors in 50- to 54-year-old patients with breast cancer could be observed. Conclusions: The decline of HRT use in Austria is associated with a reduction in breast cancer incidence in postmenopausal women. Our data underline the association between HRT and breast cancer. No significant financial relationships to disclose.
INTRAVASCULAR IMAGING COMPARISON OF TWO METALLIC LIMUS-ELUTING STENTS ABLUMINALLY COATED WITH BIODEGRADABLE POLYMERS: IVUS AND OCT RESULTS OF THE DESTINY TRIAL
Authors: Jose de Ribamar Costa, Daniel Chamie, Alexandre Abizaid, Expedito Ribeiro, George Meireles, Mauricio Prudente, Ricardo Costa, Pedro Lemos
Journal: Journal of the American College of Cardiology (2017)
Opening Remarks to the 7th World Congress of the International College of Psychosomatic Medicine
Authors: Herbert Weiner, Adolf-Ernst Meyer, W. Senf, H. Kordy, M. von Rad, W. Bräutigam, Peter E. Sifneos, Cairns Aitken, Chase Patterson Kimball, Alec Ramsay, Michael von Rad, Johannes Siegrist, Adolf-Ernst Meyer, Herbert Weiner, Adolf-Ernst Meyer, Hubert Speidel, W. Bräutigam, M. von Rad, Adolf-Ernst Meyer, Antje Haag, Christian Müller, Volker Tschuschke, Walter Volk, Reinhard Költzow, Fritz A. Muthny, Adam J. Krakowski, A. Heerlein, G. de la Parra, S. Aronsohn, F. Lolas, W. Ehlers, D. Czogalik, E. Gaus, M. Klingenburg, K. Köhle, Hertha Appelt, Bernhard Strauss, K.W. Bash, Hans-Werner Künsebeck, Wolfgang Lempa, Hellmuth Freyberger, Eike G. Fischer, Nora E. Falke, Antje Haag, Adam J. Krakowski, M.A. Rea, D.H. Hellhammer
Journal: Psychotherapy and Psychosomatics (1984)
EVIDENCE BASED THERAPY AND ITS RELATION TO WORKFORCE ATTACHMENT FOLLOWING FIRST HOSPITALIZATION FOR HEART FAILURE
Authors: Rasmus Rørth, Emil Fosbøl, Ulrik Madvig Mogensen, Kristian Kragholm, Gunnar Gislason, Christian Torp-Pedersen, Lars Køber, Søren Lund Kristensen
Journal: Journal of the American College of Cardiology (2017)
ECHOCARDIOGRAPHIC PARAMETERS OF MYOCARDIAL PERFORMANCE AFTER TRANSAPICAL VERSUS TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Mohammed Al-Hijji, Chad Zack, Patricia Pellikka, Vuyisile Nkomo, Guy Reeder, Charanjit Rihal, Mackram Eleid
Journal: Journal of the American College of Cardiology (2017)
ATRIAL FIBRILLATION IN PATIENTS WITH NON-STEMI: INSIGHTS FROM A NATIONAL DATABASE
Authors: Nilay Patel, Subir Bhatia, Prashant Patel, Shilpkumar Arora, Neil Patel, Sopan Lahewala, Harshil Shah, Ekta Aneja, Varun Kumar, Sidakpal Panaich, Apurva Badheka, Abhishek Deshmukh
Journal: Journal of the American College of Cardiology (2017)
Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients.
Authors: Neil Lorne Berinstein, Mohan Karkada, Rita Nigam, Michael Morse, John J. Nemunaitis, Gurkamal S. Chatta, Howard Kaufman, Kunle Odunsi, Genevieve Weir, Lisa MacDonald, Marianne Stanford, Marc Mansour
Journal: Journal of Clinical Oncology (2012)

2588 Background: To increase the efficacy of peptide cancer vaccines, we developed a novel vaccine platform called DepoVax , an adjuvanted water-free depot formulation with the ability to generate enhanced immune responses. Naturally processed HLA-A2 restricted peptides that are selectively presented by breast, ovarian and prostate cancer cell lines, but not by normal HLA-A2+ cells, were used as antigens with a proprietary adjuvant and a T helper peptide epitope to create a therapeutic cancer vaccine, DPX-0907. Methods: A phase I clinical study was designed to examine the safety and immune activating potential of DPX-0907 in advanced stage breast, ovarian and prostate cancer patients. A total of 23 late stage cancer patients were recruited and were divided into two dose volume cohorts in a three immunization clinical protocol. Results: DPX-0907 proved to be safe with no serious adverse effects related to the vaccine reported. Of those evaluable for immunogenicity, all breast cancer patients (3/3), most of ovarian (5/6) and one third of prostate (3/9) cancer patients demonstrated immune response to one or more of seven antigenic peptides, resulting in a 61% response rate. Immune responses correlated with achievement of CR, PR or SD to last treatment. No difference in immune response rate or magnitude was seen between the two dose groups. DPX-0907 displayed strong immune induction potential, with 73% of immune responders showing responses with just one dose of vaccine. In 83% of responders, immune responses were detected at ≥2 time points post vaccination and 64% had a persistent immune response at one month post last vaccination. Immune monitoring showed peptide-specific CD8 T cells, and these T cells were able to secrete multiple Th1 cytokines indicating their multifunctionality, a feature attributable to cells that mediate protective responses. Conclusions: These data support the ability of DPX-0907 to elicit Th1 dominated, specific immunity and support the rationale for further testing in immunologically competent cancer patients. The novel DepoVax formulation may promote multifunctional memory responses with peptides from other tumor associated antigens.
Out of Sight, Out of Mind — Behavioral and Developmental Care for Rural Children
Authors: Kelly J. Kelleher, William Gardner
Journal: New England Journal of Medicine (2017)

Interview with Dr. Heather Kovich on the challenges facing patients and physicians in rural areas of the United States. (10:07)Download Rural children from small communities in the United States are more likely than those living in cities and suburbs to have a mental, behavioral, or developmental disorder. What might cause this disparity? And how do we care for these children and their families?
PACING OVER GUIDEWIRE, STEPWISE TO MINIMALISM IN TAVI: A SINGLE CENTER EXPERIENCE
Authors: Sara Casquero Dominguez, Luis-S. Diaz de la Llera, Jose M. Cubero, Monica Fernandez Quero, Agustin Guisado Rasco, Francisco Jose Guerrero Marquez, Manuel Villa Gil-Ortega
Journal: Journal of the American College of Cardiology (2017)
UTILITY OF AN ESOPHAGEAL SCREENING PROTOCOL IN PREVENTING ATRIO-ESOPHAGEAL FISTULA AFTER ATRIAL FIBRILLATION ABLATION
Authors: Nischala Nannapaneni, Michelle Silver, Gagandeep Kaur, K. Cho William, Mohamed Labedi, Stephen Rechenmacher, Frederick Han, Mihail Chelu, Nassir Marrouche
Journal: Journal of the American College of Cardiology (2017)